National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2014

被引:318
作者
Reagan-Steiner, Sarah [1 ]
Yankey, David [1 ]
Jeyarajah, Jenny [1 ]
Elam-Evans, Laurie D. [1 ]
Singleton, James A. [1 ]
Curtis, C. Robinette [1 ]
MacNeil, Jessica [2 ]
Markowitz, Lauri E. [3 ]
Stokley, Shannon [1 ]
机构
[1] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA
[2] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA
[3] CDC, Div Sexually Transmitted Dis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA
来源
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT | 2015年 / 64卷 / 29期
关键词
ADVISORY-COMMITTEE; IMMUNIZATION PRACTICES; HPV VACCINATION; RECOMMENDATIONS;
D O I
10.15585/mmwr.mm6429a3
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
What is already known on this topic? Routine immunization is recommended for adolescents aged 11–12 years by the Advisory Committee on Immunization Practices for protection against diseases including pertussis, meningococcal disease, and human papillomavirus (HPV)–associated cancers. During 2006–2013, national coverage with ≥1 dose of tetanus-diphtheria-acellular pertussis (Tdap) vaccine and ≥1 dose of meningococcal conjugate (MenACWY) vaccine increased annually. Although ≥1-dose HPV coverage among females increased during 2007–2011, no change was observed during 2011–2012. However, during 2012–2013 and 2011–2013, ≥1-dose HPV coverage among females and males, respectively, increased. What is added by this report? During 2013–2014, vaccination coverage among adolescents aged 13–17 years increased for ≥1 dose of Tdap, ≥1 dose of MenACWY, and each HPV dose among females and males, with considerable variation in coverage by state. Although HPV vaccination coverage among females increased nationally for the second consecutive year, HPV coverage lags behind Tdap and MenACWY coverage. Seven jurisdictions achieved significant increases in ≥1- or ≥3-dose HPV vaccination coverage among females during 2013–2014, demonstrating that substantial improvement in HPV vaccination coverage is feasible. What are the implications for public health practice? Despite similar percentage point increases in coverage with Tdap and MenACWY vaccines, and ≥1 HPV dose among females in 2014, national HPV coverage estimates remain low for adolescents. Differences in coverage estimates by vaccine indicate missed opportunities for administering HPV vaccine at visits when Tdap or MenACWY vaccines are given. Routinely recommending HPV vaccine at ages 11–12 years, during the same visit and with the same emphasis used for other vaccines, is critical. Multifaceted interventions that engage clinicians and other immunization stakeholders and increase community awareness might improve HPV vaccination coverage. © 2015 Department of Health and Human Services, All Right reserved.
引用
收藏
页码:784 / 792
页数:9
相关论文
共 9 条
[1]  
Allison MA, 2013, ACAD PEDIATR, V13, P466, DOI 10.1016/j.acap.2013.03.006
[2]  
[Anonymous], 2012, MMWR-MORBID MORTAL W
[3]  
[Anonymous], The Guide to Community Preventive Services
[4]  
Curtis CR, 2014, 2014 NAT IMM C SEPT
[5]  
Elam-Evans LD, 2014, MMWR-MORBID MORTAL W, V63, P625
[6]  
Folaranmi T, 2015, MMWR-MORBID MORTAL W, V64, P608
[7]  
National Institutes of Health, 2014, UPT URG ACT PREV CAN
[8]  
Petrosky E, 2015, MMWR-MORBID MORTAL W, V64, P300
[9]  
Strikas RA, 2015, MMWR-MORBID MORTAL W, V64, P93